Guardant Health AMEA

What Guardant Health AMEA does

Guardant Health AMEA is a wholly owned subsidiary of Guardant Health, Inc. (NASDAQ: GH) and serves as the parent company's regional operating entity for Asia, the Middle East, and Africa. Headquartered in Singapore with regional offices in Tokyo, Shanghai, and Hyderabad, the entity provides precision oncology blood and tissue tests across more than 40 AMEA markets, including Guardant360 CDx (the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers), Shield and Shield MCD (blood-based colorectal and multi-cancer screening), Guardant Reveal (tissue-free molecular residual disease testing), Guardant360 TissueNext (tissue-based NGS), and GuardantOMNI (clinical-trial liquid biopsy). All samples are processed at the parent's CLIA-certified, CAP-accredited laboratory in Redwood City, California, with regional offices acting as commercial, regulatory, and partner-management hubs.

The business operates three revenue streams: per-test diagnostic services billed through healthcare systems or directly to patients (pricing not publicly disclosed, with reimbursement coverage in markets such as Japan); BioPharma Solutions, providing genomic profiling and biomarker services to pharmaceutical companies for clinical trials and drug development; and companion diagnostic partnerships with major oncology drug developers (including ENHERTU, amivantamab, camizestrant, and imlunestrant) that generate licensing and royalty revenue. Distribution is hybrid: direct enterprise sales to oncologists and hospitals via Guardant's ordering portal, supplemented by regional laboratory and distribution partners (Adicon in China, Welgene Biotech in Taiwan, Hikma in MENA) that extend reach into local clinical-trial and screening programs such as the Abu Dhabi Department of Health's Shield colorectal screening initiative.

Since becoming a wholly owned subsidiary in June 2022 (following the buyout of its prior joint venture), the entity has pursued an offensive expansion strategy focused on regulatory approvals (four Japan CDx label expansions between 2023 and 2026), geographic buildout through channel partnerships in Taiwan and the MENA region, the launch of the Shield Multi-Cancer Detection test via an insurance-channel partnership with Manulife, and population-scale screening deployment in the UAE — collectively positioning the subsidiary as the parent company's primary growth vehicle across the AMEA region.

Name

Guardant Health AMEA

Legal name

Guardant Health, Inc.

Website

https://guardanthealthamea.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Guardant Health AMEA is a Singapore-headquartered, wholly owned subsidiary of Guardant Health, Inc. that commercializes liquid and tissue biopsy precision oncology tests — including Guardant360 CDx, Shield, and Guardant Reveal — across more than 40 markets in Asia, the Middle East, and Africa, serving oncologists, hospitals, biopharmaceutical companies, and government screening programs.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)

Keywords

• Liquid biopsy tests
• Precision oncology diagnostics
• Circulating tumor DNA
• Companion diagnostic development
• Molecular residual disease

Headquarters

HQ city

Woodlands

HQ country

Singapore

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain, Others

Revenue model

1. Diagnostic Testing Services: Revenue from providing liquid biopsy and tissue biopsy tests to hospitals, physicians, and patients. Tests are ordered by healthcare professionals and sent to Guardant Health's US-based CLIA-certified laboratory for analysis.
2. BioPharma Solutions: Comprehensive genomic profiling services for biopharma companies conducting clinical trials. Includes Guardant360 and GuardantOMNI testing for drug development and companion diagnostic development.
3. Companion Diagnostic Partnerships: Regulatory-approved companion diagnostics for pharmaceutical treatments (e.g., ENHERTU, amivantamab, camizestrant, imlunestrant). Revenue from CDx regulatory approvals and pharma partnerships.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Guardant Health AMEA provides precision oncology blood and tissue tests for cancer detection, treatment selection, and recurrence monitoring across Asia, Middle East and Africa. Its portfolio includes Guardant360 CDx liquid biopsy for comprehensive tumor mutation profiling, Guardant Reveal tissue-free MRD testing, Shield blood-based colorectal cancer screening, GuardantOMNI for clinical trials, and Guardant360 TissueNext for tissue genomic profiling, complemented by BioPharma Solutions for companion diagnostic and clinical trial partnerships. All sample testing is performed in the parent's CLIA-certified, CAP-accredited US laboratory.

Product overview

Guardant Health AMEA offers a portfolio of blood and tissue tests for precision oncology spanning the cancer care continuum. The core products include Guardant Complete (guiding treatment decisions and recurrence monitoring), Shield Blood Test (colorectal cancer screening and multi-cancer detection), and BioPharma Solutions (clinical trial support). Supporting these are Guardant360 liquid biopsy (companion diagnostic for advanced solid cancers), Guardant Reveal tissue-free MRD assay (circulating tumor DNA detection for recurrence monitoring), Guardant360 TissueNext (tissue-based NGS), and GuardantOMNI (clinical trials liquid biopsy). All tests are performed in the company's CAP-accredited US laboratory.

Differentiator

Problem solved

Functional benefit

Brands

• Guardant Complete: Blood and tissue tests for guiding treatment decisions in advanced cancer and recurrence monitoring in early-stage cancer
• Shield
• Guardant360
• Guardant Reveal
• GuardantOMNI
• BioPharma Solutions

Products and services

• Guardant Complete A comprehensive blood test portfolio for oncologists guiding treatment decisions in advanced cancer and enabling recurrence monitoring in early-stage cancer across the oncology care continuum. Available across AMEA markets with sample testing performed in the parent company's CLIA-certified and CAP-accredited US laboratory.
• Shield Blood Test A blood-based screening test for colorectal cancer offering a less invasive alternative to colonoscopy. Expanded as the Shield Multi-Cancer Detection (MCD) test for multi-cancer early detection. Selected by the Abu Dhabi Department of Health for a population-level colorectal cancer screening program in January 2025.
• BioPharma Solutions A partnership offering for biopharmaceutical companies providing access to Guardant Health's liquid biopsy and tissue biopsy capabilities for clinical trial biomarker analysis, companion diagnostic co-development, and regulatory submissions across AMEA markets.
• Guardant360 Liquid Biopsy A liquid biopsy test (requiring 2 tubes of blood) for comprehensive tumor mutation profiling in patients with advanced solid cancers. Available as Guardant360 CDx with FDA, Japan PMDA, and Singapore HSA approvals, and as a companion diagnostic for targeted therapies including ENHERTU, amivantamab, camizestrant, and imlunestrant.
• Guardant Reveal A tissue-free molecular residual disease (MRD) assay (requiring 4 tubes of blood) using circulating tumor DNA (ctDNA) analysis to detect cancer recurrence and guide adjuvant therapy decisions in colorectal and other cancers, without requiring a tissue sample.
• Guardant360 TissueNext A tissue biopsy next-generation sequencing test providing comprehensive genomic profiling from tumor tissue samples for patients with cancer across AMEA markets.
• GuardantOMNI A liquid biopsy test optimized for clinical trials, offering broader analyte coverage for biopharma research and performance equivalent to Guardant Health's US-based laboratory. Enables prospective biomarker analysis in oncology drug development.

Quantifiable outcome

• 92% of Guardant Reveal tests were ordered for stage II and III colorectal cancer patients with 17.3% showing ctDNA positivity on first test
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Five partnerships are on record, tiered minor and core.

• ManulifeminorGTM or Marketing Partner · 16 March 2026Partnership to launch Shield Multi-Cancer Detection (MCD) Test in multiple markets in Asia. Manulife partnership enables distribution through insurance/healthcare coverage in Asian markets.
• Abu Dhabi Department of HealthcoreStrategic or Co-development Partner · 30 January 2025Guardant Health's Shield Test selected by Abu Dhabi Department of Health for blood-based colorectal cancer screening program. Government partnership for population health screening initiative.
• Welgene Biotech (Taiwan)coreChannel Partner/ Reseller/ Distributor · 4 November 2024Welgene Biotech offers Guardant Health's liquid biopsy and tissue biopsy NGS tests for patients with cancer in Taiwan. Provides local access to Guardant360 and Guardant360 TissueNext tests.
• Hikma PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 8 January 2024Partnership to offer cancer screening and comprehensive genomic profiling tests in the Middle East and North Africa region. Hikma serves as a distribution partner for Guardant Health products in MENA markets.
• Adicon (China)coreStrategic or Co-development Partner · 6 July 2022Strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China. Adicon offers GuardantOMNI liquid biopsy test for clinical trials with equivalent performance to Guardant Health's US-based laboratory. Guardant360 analytical validation studies completed in China, with clinical trials sample testing beginning February 2024.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Guardant Health, Inc. NASDAQ-listed parent (GH) and developer of the Guardant360, Shield, and Reveal assays that Guardant Health AMEA commercializes across Asia, Middle East and Africa; directly comparable as the originating platform and primary technology supplier.
• Foundation Medicine: Roche subsidiary offering comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) for solid tumors; directly comparable as a leading liquid and tissue NGS test provider with companion diagnostic approvals for targeted oncology therapies.
• Natera: Provider of Signatera, a tumor-informed ctDNA MRD assay for recurrence monitoring, alongside oncology and reproductive health testing; directly comparable on the MRD/liquid biopsy axis that Guardant Reveal competes in.
• Exact Sciences: Developer of Cologuard for colorectal cancer screening and OncoExTra for tumor profiling; directly comparable on the non-invasive colorectal screening axis where Guardant Shield competes, and on multi-cancer detection ambitions.
• Tempus AI: AI-enabled precision medicine company offering NGS profiling (xT, xR) and MRD (NeXT Personal) assays; directly comparable as a competing liquid and tissue NGS provider with biopharma services and data analytics.
• Caris Life Sciences: Developer of MI Profile (tissue NGS) and MI Cancer Seek (blood-based multi-cancer screening and MRD); comparable as a direct liquid biopsy and pan-cancer profiling competitor with companion diagnostic and biopharma offerings.

Broad incumbents

• NeoGenomics: Clinical oncology laboratory services company offering comprehensive tumor profiling and liquid biopsy assays (RaDaR MRD, NeoLAB); comparable as a broader oncology diagnostics incumbent with overlapping liquid biopsy and biopharma services.

Regional players

• Burning Rock Biotech: China-based oncology NGS company offering CanCatch and OncoScreen liquid biopsy panels; comparable as the leading regional liquid biopsy competitor in China where Guardant AMEA operates through the Adicon partnership.
• Genecast (Jiangsu Genecast Biotechnology): China-based precision oncology company offering ACT (Comprehensive Therapy) liquid biopsy panels for solid tumors; comparable as a regional AMEA liquid biopsy competitor with similar tumor profiling and biopharma offerings.

Emerging players

• Predicine: US-China cross-border liquid biopsy company offering PredicineATLAS and PredicineHEME ctDNA assays with companion diagnostic and biopharma services; comparable as an emerging player with hybrid US/Asia footprint targeting the same AMEA biopharma clinical trial market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/guardantamea
• Facebookfacebook.com/GuardantHealthAMEA
• LinkedInlinkedin.com/company/guardanthealthamea

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Guardant Health AMEA